Nope if this were true that would be a gold strategy for hundreds of hedge funds out there...buy share of biotechs before approval where the FDA did the same...and sell upon approval. If this were true these hedge funds would have already raised CYDY stock price to $20+. This is not the case so...this does not work.
I agree and not only that, Leronlimab was given a billing code. I believe it was the only one or a very select few that got billing code prior to at least a EUA or approval. Wall Street darling HGEN's drug did not even though it got Government funding and is also at the end of Phase 3.